BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

Group 1 - BioCryst Pharmaceuticals will report its fourth quarter 2025 financial results on February 26, 2026 [1] - A conference call and webcast will be hosted by BioCryst management at 8:30 a.m. ET on the same day to discuss the financial results and provide a corporate update [1] - The live call can be accessed by domestic and international callers through specific phone numbers, and a live webcast will be available on the company's website [2] Group 2 - BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases [3] - The company has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class therapeutics [3]